INTERPACE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.45 USD | 0.00% |
|
+7.41% | +34.26% |
| May. 09 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Presenter SpeechJack Stover (Executives)Good morning, ladies and gentlemen. Welcome to the 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.
Sector
Managed Healthcare
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +34.26% | 6.35M | |
| +5.51% | 1.29B |
- Stock Market
- Equities
- IDXG Stock
- News Interpace Biosciences, Inc.
- Transcript : Interpace Biosciences, Inc. - Shareholder/Analyst Call